SonoVascular, Inc.
Daniel Estay is a seasoned executive in the medical technology field, currently serving as the Founder and CEO of SonoVascular, Inc., where a multi-mechanism SonoThrombectomy™️ system is being developed for endovascular treatment of venous and arterial diseases. As a Mentor-in-Residence for Duke's Office for Translation & Commercialization, Daniel Estay provides strategic insights for medical device start-ups. Previous roles include Partner at OneMedTech Advisors, President at Verathon, and various leadership positions at Abbott, The Getz Group, Andrx Corporation, Johnson & Johnson, and LeMare Medical, Inc. Daniel Estay holds an MBA in International Business from the University of Miami and a Bachelor of Science in Business Administration from Syracuse University.
This person is not in any teams
SonoVascular, Inc.
SonoVascular has developed a novel pharmaco-mechanical ultrasound facilitated thrombectomy system, SonoThrombectomy™, that utilizes microbubble-mediated cavitation as a core enabling mechanism of action to remove blood clots more effectively. The system uniquely combines: (i) ultrasound, (ii) microbubbles, (iii) low dose thrombolytic drug, and (iv) mechanical retrieval and aspiration, delivered via an integrated intravascular catheter system. SonoVascular’s technology has been engineered to address and overcome the deficiencies and limitations of current interventional devices. Its design enables safe and effective treatment in the catheterization laboratory (cathlab), maximizes the reduction in clot burden, enhances the delivery and reduces the dose and duration of thrombolytics to levels that optimize safety and effectiveness, and eliminates the need for patients to be treated in the ICU.